Further relevance as a therapeutic target for immunological diseases is shown by the recent finding that Laquinimod, a drug being evaluated for the treatment of MS, activates the AhR pathway and upregulates CYP1A1 and AHRR26. Here, CYP1A1 is linked to myeloid sarcoma.